Today's current affairs are readyRead
Super Current Affairs
हिंदीEN
PolityStory 4 of 30

Supreme Court Scrutinizes NPPA on Drug Pricing, Questions ₹8,447 Cr Pending Recovery from Pharma Firms

27 October 2026The HinduHindustanIndian ExpressDainik Bhaskar4 sources3 min3 questions

How much it matters for each exam

  • UPSC8/10
  • BPSC7/10
  • UPPSC7/10
  • SSC7/10

1At a glance

The Supreme Court has questioned the government's 'calibrated' approach to drug price control, emphasizing that economic policy cannot override citizens' right to affordable healthcare. It scrutinized the National Pharmaceutical Pricing Authority (NPPA) for delays in capping trade margins on essential medicines and highlighted huge pending recoveries from pharmaceutical companies for overcharging.

  • Judicial Scrutiny

    The Supreme Court questioned the Centre's drug pricing policy, stating economic policy cannot take precedence over citizens' lives.

  • Price Control Action

    NPPA capped trade margins on 137 non-scheduled anti-cancer medicines at 30% of MRP, effective from November 9, 2026.

  • Huge Pending Dues

    The NPPA has recovered only about 16% (₹1,582.4 Cr) of the over ₹10,000 crore demanded from pharma firms for overcharging.

2Facts to remember

Tap a card to see the answer. Try to recall it first.

3Detailed analysis

Context / Background

India regulates drug prices through the Drugs (Prices Control) Order (DPCO), 2013, under the Essential Commodities Act, 1955. The National Pharmaceutical Pricing Authority (NPPA) fixes ceiling prices for drugs listed in the National List of Essential Medicines (NLEM). Drugs outside this 'scheduled' list are not directly price-controlled, often leading to high trade margins, especially for critical medicines like anti-cancer drugs, burdening patients.

Core Analysis & Implications

The Supreme Court's intervention highlights the tension between public health and market economics. The Centre's 'calibrated approach' argues for balancing affordability with encouraging pharmaceutical innovation and investment. However, the Court's focus on the NPPA's inaction and the massive ₹8,447 crore pending recovery points to weak enforcement. The distinction between 'scheduled' and 'non-scheduled' drugs creates a regulatory loophole, allowing disproportionate profiteering in the supply chain, which the Court termed a 'game'.

Future Outlook / Way Forward

The Court has reserved its order, and its final judgment could mandate stricter enforcement of the DPCO, potentially expanding the list of scheduled drugs or mandating uniform trade margins. This may lead to stronger price control mechanisms, impacting pharmaceutical companies' profitability and potentially triggering debates on the need for a holistic healthcare policy that ensures affordability without stifling industry growth.

4Background GK

Textbook concepts you need to understand this news

National Pharmaceutical Pricing Authority (NPPA)
An independent regulator under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, established in 1997. It fixes and revises prices of controlled bulk drugs and formulations and enforces their availability.
Drugs (Prices Control) Order (DPCO)
An order issued by the Government of India under Section 3 of the Essential Commodities Act, 1955, to control the prices of essential medicines. The current order is DPCO 2013.
National List of Essential Medicines (NLEM)
A list prepared by the Ministry of Health and Family Welfare containing medicines that satisfy the priority healthcare needs of the majority of the population. Drugs on this list are subject to price control (scheduled formulations) under the DPCO.

5How exams will ask this

  • Data: ₹8,447.4 crore (pending recovery by NPPA as of March 2026) and 30% (trade margin cap for 137 anti-cancer drugs).
  • Nodal Body: National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals.
  • Legal Point: Drugs (Prices Control) Order, 2013, issued under the Essential Commodities Act, 1955.

Don't make this mistake!

Confusing 'scheduled' (price-controlled under DPCO) with 'non-scheduled' drugs, or swapping the trade margin percentage (e.g., 16% retailer margin vs. 30% overall cap). They may also ask which ministry NPPA falls under (Chemicals and Fertilizers, not Health).

Write these in mains answers

Judicial activism in public health, Right to Health under Article 21, Regulatory capture vs. public welfare, Trade margin rationalization

6Practice questions

Pick an answer, then read the explanation.

  1. Q1Hard

    Consider the following statements regarding the news on drug price controls:

    1. 1.The Supreme Court questioned the National Pharmaceutical Pricing Authority for its delay in capping trade margins on essential medicines.
    2. 2.The Drugs (Prices Control) Order, 2013, mandates a uniform retailer margin of 30% on all scheduled drugs.
    3. 3.As per a news report cited by the Court, the NPPA had recovered over ₹8,400 crore from pharmaceutical companies in overcharging cases as of March 2026.

    Which of the statements given above is/are correct?

  2. Q2Medium

    According to the Supreme Court proceedings reported in the article, what is the trade margin cap set by the NPPA on 137 non-scheduled anti-cancer medicines?

  3. Q3Medium

    What was the primary argument put forth by the Centre in the Supreme Court in defense of its drug pricing policy?

7All sources

Today's quizYou read it. Now test it.20 questions · instant scoreStart

More from this day

All stories of 27 October 2026 →
Daily Quiz